Souders Financial Advisors Gilead Sciences, Inc. Transaction History

Souders Financial Advisors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 04, 2022	SELL	$57.92 - $72.58 $2.27 Million - $2.84 Million	-39,151 Closed	0 $0
Q4 2021 Feb 04, 2022	BUY	$64.88 - $73.64 $58,067 - $65,907	895 Added 2.34%	39,151 $2.84 Million
Q3 2021 Nov 03, 2021	BUY	$67.69 - $73.03 $38,380 - $41,408	567 Added 1.5%	38,256 $2.67 Million
Q2 2021 Aug 09, 2021	BUY	$63.47 - $69.35 $35,352 - $38,627	557 Added 1.5%	37,689 $2.6 Million
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $290,640 - $331,620	-4,844 Reduced 11.54%	37,132 $2.4 Million
Q4 2020 Feb 09, 2021	SELL	$56.65 - $64.55 $28,608 - $32,597	-505 Reduced 1.19%	41,976 $2.45 Million
Q3 2020 Nov 12, 2020	BUY	$62.1 - $78.08 $1.36 Million - $1.7 Million	21,835 Added 105.76%	42,481 $2.58 Million
Q2 2020 Aug 11, 2020	SELL	$72.34 - $84.0 $758,267 - $880,488	-10,482 Reduced 33.67%	20,646 $1.59 Million
Q1 2020 May 12, 2020	BUY	$62.63 - $80.22 $1.95 Million - $2.5 Million	31,128 New	31,128 $2.33 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Souders Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Souders Financial Advisors with notifications on news.